Evaluation

INTRODUCTION: In Spain, the offer of prevention programmes is very varied and structured, but today the challenge remains how to put evidence into practice. European Commission define a best practice as “a relevant policy or intervention...

There is little study of lifetime trauma exposure among individuals engaged in medication treatment for opioid use disorder (MOUD). A multisite study provided the opportunity to examine the prevalence of lifetime trauma and differences by gender, PTSD status, and chronic pain.

BACKGROUND: Drug dependence is a public health problem that requires trained professionals to effectively address this issue. The aim of this study was to analyse postgraduate university training programs specialising in addictions in Spain...

Background: Over the past decade, drug-related overdoses have seen a significant rise both in North America and globally. The COVID-19 pandemic has further emphasised the urgent need for safer supply programs to replace unregulated...

BACKGROUND: Substance use increases the risk of damage to executive and cognitive functions. Manifested by a range of clinical symptoms, such impairments may affect people’s coping with everyday activities and their abilities to establish...

The DIMS annual report 2022 covers the concentrations, adulterations, and other relevant information produced by DIMS in the past year, and in doing so forms a topical image of the Dutch drug market. Spread out over all Dutch provinces, the...

Background: Physical health problems are common in people receiving opioid agonist treatment (OAT). A study was conducted on these health issues in OAT patients in the Czech Republic and Norway from 2010 to 2019, with a focus on gender...

Abstract Objectives Xylazine is an α2-agonist increasingly prevalent in the illicit drug supply. Our objectives were to curate information about xylazine through social media from people who use drugs (PWUDs). Specifically, we sought to...